Growth hormone secretagogues: history, mechanism of action and clinical development

Junichi Ishida¹, Masakazu Saitoh¹, Nicole Ebner¹, Jochen Springer¹, Stefan D Anker¹, Stephan von Haehling ¹, Department of Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany

Abstract
Growth hormone secretagogues (GHSs) are a generic term to describe compounds which increase growth hormone (GH) release. GHSs include agonists of the growth hormone secretagogue receptor (GHS-R), whose natural ligand is ghrelin, and agonists of the growth hormone-releasing hormone receptor (GHRH-R), to which the growth hormone-releasing hormone (GHRH) binds as a native ligand. Several GHSs have been developed with a view to treating or diagnosing GH deficiency, which causes growth retardation, gastrointestinal dysfunction and altered body composition, in parallel with extensive research to identify GHRH, GHS-R and ghrelin. This review will focus on the research history and the pharmacology of each GHS, which reached randomized clinical trials. Furthermore, we will highlight the publicly disclosed clinical trials regarding GHSs.

Address for correspondence: Corresponding author: Stephan von Haehling, MD, PhD, Department of Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany
Robert-Koch-Strasse 40, 37075 Göttingen, Germany, Tel: +49 (0) 551 39-20911, Fax: +49 (0) 551 39-20918
E-mail: stephan.von.haehling@med.uni-goettingen.de

Key words: GHRPs, GHSs, Ghrelin, Morelins, Body composition, Growth hormone deficiency,

1. Introduction

The term growth hormone secretagogues (GHSs) embraces compounds that have been developed to increase growth hormone (GH) release. GHSs include agonists of the growth hormone secretagogue receptor (GHS-R), whose natural ligand is ghrelin, and agonists of the growth hormone-releasing hormone receptor (GHRH-R), to which the growth hormone-releasing hormone (GHRH) binds as a native ligand. Several GHSs have been developed with an aim to treat or diagnose GH deficiency, namely growth retardation, gastrointestinal dysfunction, and altered body composition, in parallel with extensive research to identify GHRH, GHS-R, and ghrelin. Ghrelin is a 28 amino-acid containing polypeptide that is mainly synthesized in the stomach. Its activity stimulates growth hormone secretion and appetite, resulting in net body-weight gain. From a historical angle, growth hormone releasing peptides (GHRPs) were found prior to the discovery of ghrelin and the ghrelin receptor. Subsequently growth hormone secretagogues, i.e. ghrelin peptide mimetics were developed. Only later, the GHS type 1a receptor (GHS-R1a) was discovered. Finally, ghrelin was successfully isolated as a natural ligand of GHS-R1a from stomach substrates in 1999. This background sparked the development of ghrelin receptor agonists, GHRPs, and GHSs, some of which reached testing in clinical trials. A vast array of indications of ghrelin receptor agonists has been evaluated including growth retardation, gastrointestinal dysfunction, and altered body composition, some of which have received approval by the FDA. This review will focus on the research history and the pharmacology of ghrelin receptor agonists. Publicly disclosed clinical trials regarding GHSs will be discussed in this regard.

2. History

In 1976, Bowers and colleagues demonstrated that derivative forms of met-enkephalin selectively promoted GH secretion in rat pituitary cells [1], which indicated a therapeutic potential of a derivative of met-enkephalin as an alternative of GH replacement therapy, that used to be expensive and required a daily painful injection. Based on this concept, several novel derivatives of met-enkephalin were developed. Among them, GHRP6 and GHRP2, reported in 1984 and 1992 respectively, have highly promoted GH secretion, compared to the natural GHRH [2,3]. Subsequently, GHS-R was cloned and shown to be the target of GHRPs in 1996 [4]. Finally, ghrelin, an endogenous ligand of the GHRP receptor, was discovered in rat stomach by Kojima and Kangawa in 1999 [5]. This progress of research regarding ghrelin and its related molecules is referred to a typical example of reverse pharmacology, namely the
discovery of GHSs was followed by the identification of the GHS-R and its endogenous ligand, ghrelin. Therefore, GHSs have been selected for clinical applications such as growth retardation, gastrointestinal dysfunction, and impaired body composition, in parallel with the exploratory research of endogenous substances.

3. Pharmacology

Since ghrelin has various physiological activities, ghrelin receptor agonists, mimicking the actions of ghrelin, represent pharmacological targets in several conditions. Here, we describe pharmacology of ghrelin receptor agonists in the following paragraphs, divided into three clinical indications, namely growth retardation, gastrointestinal dysfunction, and impaired body composition. Chemical formula, synonyms, molecular weight, manufacturer (patent holder), route of administration, pharmacokinetics, and pharmacodynamics of GHSs are summarized in Table 1, and chemical structures of GHSs are depicted in Figure 1.

Figure 1. Chemical structures of GHSs
Chemical structures are provided by Pubchem [85]. Blue, red and yellow circle indicates a group of GHSs for the clinical indication of abnormal body composition, growth retardation and gastrointestinal dysfunction, respectively.
Table 1: Growth hormone secretagogues

<table>
<thead>
<tr>
<th>Substance</th>
<th>Synonyms</th>
<th>Molecular formula</th>
<th>MW</th>
<th>First patent</th>
<th>Manufacturer</th>
<th>Route</th>
<th>Pharmacokinetics / pharmacokinetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sermorelin</td>
<td>GRF 1-29, Geref</td>
<td>C₁₆₆H₂₆₆N₆₆O₁₂₅</td>
<td>3357.9</td>
<td>1990</td>
<td>EMD Serono</td>
<td>IV, SC</td>
<td>Humans. Tmax 5-20 min. T1/2 11-12 min after SC administration.</td>
</tr>
<tr>
<td>Examorelin</td>
<td>EP-23905, MF-6003, Hexarelin</td>
<td>C₁₃₀H₂₁₀₂N₁₀₂O₁₀</td>
<td>887.1</td>
<td>1994</td>
<td>Mediolanum Farmaceutici</td>
<td>PO, IN</td>
<td>Humans. After IV administration, plasma peak GH concentrations 30 min, half-life of GH 55 min</td>
</tr>
<tr>
<td>Tabimorelin</td>
<td>NN-703, Growth hormone releasing peptide-2, KP-102, GPA-748, NNC 26-0161</td>
<td>C₁₅₀H₂₁₀₂N₁₀₂O₁₀</td>
<td>528.7</td>
<td>1997</td>
<td>Novo Nordisk</td>
<td>PO</td>
<td>Inhibition of CYP3A4 activity.</td>
</tr>
<tr>
<td>Pralmorelin</td>
<td>EP-23905, MF-6003, Hexarelin</td>
<td>C₁₅₀H₂₁₀₂N₁₀₂O₁₀</td>
<td>818.0</td>
<td>2005</td>
<td>Kaken Pharmaceutical</td>
<td>PO, IV</td>
<td>Humans. IV administration, T1/2 0.42 - 0.69 hrs, mainly excreted in bile.</td>
</tr>
<tr>
<td>Ipamorelin</td>
<td>NN-703, Growth hormone releasing peptide-2, KP-102, GPA-748, NNC 26-0161</td>
<td>C₁₅₀H₂₁₀₂N₁₀₂O₁₀</td>
<td>711.9</td>
<td>1998</td>
<td>Novo Nordisk, Helsinn Therapeutics</td>
<td>IV, SC, IN</td>
<td>Humans. IV administration. T1/2 2 hrs, a clearance of 0.078 L/h/kg, a volume of distribution at steady-state of 0.22 L/kg, a single peak of GH release at 0.67 hrs.</td>
</tr>
<tr>
<td>Ulimorelin</td>
<td>Tzp-101</td>
<td>C₁₅₀H₂₁₀₂N₁₀₂O₁₀</td>
<td>538.7</td>
<td>2005</td>
<td>Lyric Pharmaceuticals, Tranzyme Pharma</td>
<td>IV</td>
<td>Small volume of distribution (99-180 mL/kg following single IV administration in patients with gastroparesis, T1/2 10-20 hrs in healthy subjects.</td>
</tr>
<tr>
<td>Relamorelin</td>
<td>RM-131, BIM-28131, BIM-28163</td>
<td>C₁₅₀H₂₁₀₂N₁₀₂O₁₀</td>
<td>791.0</td>
<td>2007</td>
<td>Ipsen, Rhythm Pharmaceuticals</td>
<td>SC</td>
<td>Humans. Tmax 0.74 hrs, T1/2 ~ 4.5 hrs.</td>
</tr>
<tr>
<td>TZP-102</td>
<td>NA</td>
<td>C₁₅₀H₂₁₀₂N₁₀₂O₁₀</td>
<td>528.7</td>
<td>2009</td>
<td>Tranzyme Pharma</td>
<td>PO</td>
<td>Beagles. After PO administration, plasma peak GH concentrations 120 min, half-life of GH 4 - 6 hrs</td>
</tr>
<tr>
<td>Ibutamoren</td>
<td>MK-677, L-163191</td>
<td>C₁₅₀H₂₁₀₂N₁₀₂O₁₀</td>
<td>5195.9</td>
<td>1996</td>
<td>Merck</td>
<td>PO</td>
<td>Bioavailability less than 4% after SC administration in healthy subjects. Tmax 0.15hrs. A volume of distribution 9.4 and 10.5 L/kg in healthy subjects and HIV-infected patients respectively. T1/2 26 and 38 min respectively.</td>
</tr>
<tr>
<td>Tesamorelin</td>
<td>TH-9507, Egrifta</td>
<td>C₁₅₀H₂₁₀₂N₁₀₂O₁₀</td>
<td>5195.9</td>
<td>1996</td>
<td>Theratechnologies</td>
<td>SC</td>
<td></td>
</tr>
<tr>
<td>Capromorelin</td>
<td>CP-424391, Entyce</td>
<td>C₁₅₀H₂₁₀₂N₁₀₂O₁₀</td>
<td>505.6</td>
<td>1997</td>
<td>Pfizer Aratana</td>
<td>PO, IV, SC</td>
<td>Rats. After PO administration, Tmax 1 hr, T1/2 2.4 hrs, excretion: feces (77-84%) and urine (7-15%)</td>
</tr>
<tr>
<td>Anamorelin</td>
<td>ONO-7643, RC-1291, ST-1291</td>
<td>C₁₅₀H₂₁₀₂N₁₀₂O₁₀</td>
<td>546.7</td>
<td>2003</td>
<td>Helsinn Therapeutics, Ono Pharmaceutical</td>
<td>PO</td>
<td>Humans. Tmax 0.5 - 2.0 hrs, T1/2 7 hrs, excretion: feces (92%) and urine (8%)</td>
</tr>
</tbody>
</table>
3.1. Growth retardation: Sermorelin, examorelin, tabimorelin, pralmorelin, macimorelin

3.1.1. Sermorelin

Sermorelin is a 29 amino-acids analogue of human GHRH with a fully functional activity of GHRH. In subcutaneous administration of 2 mg sermorelin, peak concentrations were reached in 5-20 minutes, and sermorelin was rapidly cleared from the circulation, with clearance values in adults ranging between 2.4-2.8 L/min. The half-life of sermorelin was short, 11-12 minutes after either intravenous or subcutaneous administration. Since sermorelin, intravenously or subcutaneously administered, specifically stimulate GH secretion from the pituitary gland without any significant change in prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), insulin, cortisol, glucose, glucagon, or thyroid hormone levels [6,7], sermorelin was approved for the treatment of growth retardation in children in 1997. However, sermorelin was discontinued in 2008 due to difficulties in the manufacturing process of the active ingredient used to produce commercially-supplied sermorelin, but not due to safety issues.

3.1.2. Examorelin

Examorelin, a hexapeptide, was derived from GHRP-6 by Mediolanum Farmaceutici in Spain [8]. Examorelin increased GH secretion in vitro and in vivo in a dose-dependent manner [8,9]. In healthy male adults, intravenous examorelin increased plasma GH values, which reached their peak value at approximately 30 min and decreased to baseline levels within 240 min with a half-life of about 55 min [10]. Examorelin was well-tolerated, while examorelin experiences reversible diminished efficacy by 50 to 75% over the course of weeks to months [11]. Examorelin reached phase II clinical testing for the treatment of growth hormone deficiency but the results have not been officially reported yet [12]. One study has discussed positive inotropic effects of examorelin for the treatment of heart failure [13]

3.1.3. Tabimorelin

Tabimorelin, one of the first generation GHSs, was derived from ipamorelin by Novo Nordisk [14]. Tabimorelin increased GH release as well as production of insulin-like growth factor-1 (IGF-1) and IGF binding protein 3 (IGFBP-3) with subtle changes in adrenocorticotropic hormone (ACTH), cortisol and prolactin in healthy male subjects [15,16], while only 11% of patients with GHD responding to tabimorelin with a peak GH concentration >5 g/l [17]. Furthermore, tabimorelin was reported to inhibit CYP3A4, which may lead to unexpected side-effects [18]. To overcome this drawback, Novo Nordisk has developed some compounds derived from tabimorelin including NNC-26-1167, although these have never been testing in clinical studies.

3.1.4. Pralmorelin

Pralmorelin, also known as GHRP2, is an an orally active, short-acting, synthetic peptide that was originally developed by Polygen in Germany and Tulane University in the U.S. and then acquired by Kaken Pharmaceutical Company in Japan [19]. In rats, pralmorelin was associated with 2-3-fold increase in GH release compared to GHRP6 after intravenous administration. Plasma GH levels after a single pralmorelin administration were higher than 15 g/l in healthy subjects, lower than 15 g/l values were observed in patients with severe GHD [20].

3.1.5. Macimorelin

Macimorelin, an orally-active small molecule GHS, was developed through the modification of the tripeptide EPS1389, which was synthesized by downsizing examorelin, by AEterna Zentaris in Canada. A previous study revealed that macimorelin, compared to examorelin and administered subcutaneously, significantly and selectively increased GH release in rats and healthy volunteers, [21]. Subsequently, in a phase I clinical testing, macimorelin increased serum GH levels in a dose-dependent manner, and GH levels remained high for approximately 120 minutes after oral or intraduodenal administration [22].

3.2. Gastrointestinal indications: Ipamorelin, ulimorelin, relamorelin, TZP-102

Ghrelin has been shown to exert prokinetic effects on gastrointestinal motility via the vagus and pelvic nerve. Since the pharmacological potential of ghrelin is hampered by its short half-life, GHSs with enhanced pharmacokinetics were developed. Centrally penetrant GHSs stimulate defecation and improve impaired bowel functions in animals and humans [23].

3.2.1. Ipamorelin

Ipamorelin, a pentapeptide derived from GHRP-1, was originally developed by Novo Nordisk in Denmark [24]. Ipamorelin significantly and selectively increased plasma GH levels without any change in prolactin, FSH, LH, thyroid-stimulating hormone, ACTH or cortisol levels in swines [24]. Ipamorelin induced GH release with a peak at 0.67h after administration and a rapid decline in healthy subjects [25]. In a rat model of postoperative ileus (POI), repetitive intravenous ipamorelin administration was associated with a significant increase in fecal pellet output, food intake, and body weight gain [26].

3.2.2. Ulimorelin
Ulimorelin, a small molecule GHS with low clearance (≈7 mL/h/kg), small volume of distribution (≈114 mL/kg) and a prolonged half-life of 10 to 20 hours, was developed by the Canadian company Tranzyme Pharma [27,28]. Interestingly, ulimorelin improved decreased gastrointestinal motility without an increase in GH release in rats and humans [29,30]. In a clinical trial to investigate the safety and efficacy of ulimorelin in patients with diabetic gastroparesis, defecation was significantly increased as a side effect, supporting a therapeutic potential for impaired lower gastrointestinal function such as POI and chronic constipation [31]. On the other hand, a recent study reported that ulimorelin could unexpectedly cause hypotension through the blockade of α₂-adrenoceptors [32].

### 3.2.3. Relamorelin

Relamorelin, a synthetic pentapeptide, was developed by Rhythm Pharmaceuticals in the US. Relamorelin binds to GHS-R with approximately 3-fold higher affinity than ghrelin itself, and it increases plasma GH, prolactin, and cortisol levels [33]. Moreover, relamorelin improved gastrointestinal motility with a 100-times greater potency compared to ghrelin in rat models of POI and morphin-induced ileus [34]. Relamorelin also promoted gastric emptying in patients with diabetic gastroparesis [35,36]. Based on these mechanisms and findings, relamorelin has drawn much attention as a therapeutic option for gastrointestinal dysfunction such as POI, diabetic gastroparesis, or chronic constipation.

### 3.2.4. TZP-102

TZP-102, a small molecule macrocyclic peptide, was developed as a second generation ghrelin agonist, following ulimorelin by Tranzyme Pharmaceutical [37]. TZP-102 is orally active and has a prolonged half-life [37]. TZP-102 reached phase II clinical trials, although detailed information regarding TZP-102 has not been publicly disclosed.

### 3.3. Body composition indication: Ibutamoren, tesamorelin, capromorelin, anamorelin, macimorelin

Since both GH and IGF-1 increase muscle mass and muscle strength and decrease fat mass [38-40], GHSs have been considered as drug candidates for the treatment of untoward alterations in body composition, such as HIV-associated lipodystrophy, sarcopenia, frailty, and cachexia. Ibutamoren, tesamorelin, capromorelin, anamorelin and macimorelin have been tested in these clinical conditions.

### 3.3.1. Ibutamoren

Ibutamoren, a low-molecular-weight orally-active GHS with a prolonged half-life, was developed by Merck in the U.S. [41]. Ibutamoren increases plasma levels of GH levels and IGF-1 without significant changes in cortisol values in beagle dogs and humans [42-44]. As a result, ibutamoren increased fat-free mass in obese subjects [43] and reversed diet-induced muscle wasting in healthy subjects under catabolic conditions [45]. On the other hand, ibutamoren was reported to be associated with an increased risk of heart failure in a randomized trial enrolling patients with hip fracture [46].

### 3.3.2. Tesamorelin

Tesamorelin, a synthetic analogue of hGHRH with the addition of a trans-3-hexenoyl moiety to Tyr1 of the amino acid sequence, was developed by Theratechnologies, Inc. in Canada. Tesamorelin was resistant to dipeptidyl aminopeptidase-IV deactivation, resulting in a longer half-life compared to GHRH in animals and humans [47,48]. Since GHRH could be a better treatment option than GH replacement in HIV-infected patients with lipodystrophy [49], tesamorelin has also progressed to clinical trial testing to examine the safety and efficacy in HIV-associated lipodystrophy.

### 3.3.3. Capromorelin

Capromorelin, an orally-active GHS with a short half-life, was developed by Pfizer in the US [50]. Since capromorelin increased GH and IGF-1 levels, resulting in body weight gain in rats and dogs [51], the U.S. Food and Drug Administration (FDA) approved capromorelin as a therapeutic option for appetite improvement in anorexic dogs. Capromorelin is also considered as a drug candidate for the treatment of elderly subjects with sarcopenia and/or frailty [52]. However, it is unlikely that the agency will provide approval for this indication, because the ageing process is per se not viewed as a pathological condition.

### 3.3.4. Anamorelin

Anamorelin, an orally-active, small-molecule GHS with a prolonged half-life of 7 hours, was developed by Helsinn Therapeutics [53]. Anamorelin increased plasma levels of GH, IGF-1, and IGFBP-3 as well as body weight in a dose-dependent manner without significant changes in the levels of other anterior pituitary hormones or glucose [54,55]. Anamorelin has progressed to phase III clinical testing to examine the safety and efficacy in patients with non-small cell lung carcinoma (NSCLC)-induced cachexia [56,57], however, the European Medicines Agency rejected the application for approval in fall 2017.

### 4. Results of major clinical trials and current status

Results of major clinical trials and current status of each GHS are summarized in Tables 2 and 3, respectively.

---

Journal of Cachexia, Sarcopenia and Muscle – Rapid Communications| Volume 2| Issue 2| e00077| Page 5
4.1. Growth retardation: Sermorelin, examorelin, tabimorelin, pralmorelin, macimorelin

Several clinical trials have been performed and completed to evaluate the safety and efficacy of GHSs for the diagnosis and/or treatment of growth hormone deficiency, while most results have not been publicly disclosed, which indicates disappointing results, probably due to safety concerns or lack of efficacy over prolonged treatment, or due to unexpected side effects.

4.1.1. Sermorelin

Sermorelin was initially developed as a diagnostic tool for growth hormone deficiency [58]. Sermorelin rapidly and specifically increased GH release in healthy children, but not in those with growth hormone deficiency compared to existing provocative tests [59], resulting in an approval for this indication by the FDA in 1990. Subsequently, 6 months’ treatment with sermorelin showed a significant increase in GH release and growth velocity in GH-deficient children [60,61], and preliminary data suggested the efficacy of sermorelin treatment for 36 months [59]. Based on these findings, sermorelin was approved by the FDA for the treatment of idiopathic growth hormone deficiency in children with growth failure in 1997.

Sermorelin was also tested in other clinical indications, namely muscle wasting in elderly people with GH insufficiency, lipodystrophy in HIV-infected patients [49], and impaired cognition in elderly subjects [62]. The results seemed promising, but further development has not been reported. In addition, sermorelin has been discontinued by EMD Serono in 2008, because of the supply issues of the active ingredient.

4.1.2. Examorelin

Examorelin reached phase II clinical trials for the treatment of growth hormone deficiency and that of congestive heart failure, but the results have not been disclosed. Finally, Mediolanum Farmaceutica discontinued producing examorelin for strategic reasons in 2005 [13].

4.1.3. Tabimorelin

Tabimorelin failed to show beneficial effects on GH release in adult patients with GHD in a phase II trial [17]. Furthermore, tabimorelin was reported to inhibit CYP3A4, which may lead to unexpected side-effects [18]. To overcome this drawback, Novo Nordisk has developed some compounds derived from tabimorelin, such as NNC-26-1167, although these have not been evaluated in clinical trials so far.

4.1.4. Pralmorelin

Plasma GH levels after single pralmorelin administration were higher than 15 µg/l in healthy subjects, while lower than 15 µg/l in patients with severe GHD [20], which led to the approval of pralmorelin for the diagnosis of GHD in Japan in 2004 [63]. Moreover, pralmorelin has been shown to stimulate growth velocity following 8 months of intermittent therapy in GHD children with intact hypothalamic–pituitary (H-P) axes [64]. Although pralmorelin reached phase II clinical trials for the treatment of short stature, further development was discontinued. This was presumably because pralmorelin failed to increase plasma GH levels sufficiently in patients with GHD [19].

4.1.5. Macimorelin

A phase III clinical trial has shown that oral macimorelin was effective for the diagnosis of adult GHD with 82% sensitivity and 92% sensitivity at an optimal GH cut point of 2.7 ng/mL, which was comparable with GHRH and arginine test [65]. Another phase III clinical trial has been completed in 2016, to compare its efficacy with the insulin tolerance test (ClinicalTrial.gov Identifier: NCT02558829), and AEtima Zentaris announced to pursue approvals of macimorelin for this indication by the FDA and the European Medicines Agency (EMA) in March 2017. In addition, a phase II clinical trial for the treatment of cancer cachexia is also currently ongoing (ClinicalTrial.gov Identifier: NCT01614990).

4.2. Gastrointestinal indication: Ipamorelin, ulimorelin, relamorelin, TZP-102

4.2.1. Ipamorelin

Ipamorelin was introduced to phase II clinical trials for the treatment of POI, sponsored by Helsinn Therapeutics. However, in patients undergoing bowel resection, ipamorelin did not shorten the time to first meal intake compared with placebo [66]. The following phase II clinical trial did not show any significant difference in measurable colonic functions between ipamorelin and placebo [67]. Due to these disappointing results, its development was discontinued.

4.2.2. Ulimorelin

Based on the favorable effects of ulimorelin on gastrointestinal function in animal experiments and small clinical studies, ulimorelin has progressed to randomized clinical trials for the treatment of diabetic gastroparesis or POI. In patients with diabetic gastroparesis, ulimorelin improved gastrointestinal symptoms such as vomiting and appetite loss [31], while there were no significant differences in improvement of gastrointestinal function between patients with POI taking ulimorelin and those taking placebo [68]. Because of this insufficient efficacy and the risk of unexpected hypotension [32], its
development for gastrointestinal indications has been discontinued [69].

4.2.3. Relamorelin

A phase I clinical trial showed that relamorelin, compared to placebo, greatly accelerated gastric emptying in female patients with diabetic gastroparesis [35]. Subsequently, a phase II clinical trial demonstrated that relamorelin significantly reduced vomiting frequency and enhanced gastric emptying in patients with diabetic gastroparesis [70]. These results allowed the FDA to grant Fast Track designation for relamorelin for the treatment of diabetic gastroparesis in 2016.

The safety and efficacy of relamorelin on chronic constipation has also been evaluated. In a phase II clinical trial, relamorelin significantly reduced the symptoms of constipation and accelerated colonic transit in female patients with chronic constipation [71]. Furthermore, the same study showed that relamorelin rapidly increased colonic contractions without any change in background irregular contractions [72]. These promising effects of relamorelin on gastrointestinal disorders might lead to a wider range of clinical applications in the near future.

4.2.4. TZP-102

A phase IIa trial demonstrated that TZP-102 reduced abdominal symptoms without significant improvement in gastric emptying in patients with diabetic gastroparesis, compared to placebo [73]. Subsequently, phase IIb trials failed to show significant difference in improvement of gastrointestinal motility between TZP-102 and placebo [74]. No developments regarding TZP-102 have been recently updated, since Ocura Therapeutics merged with Tranzyme Pharmaceutical, the manufacturer of TZP-102, in 2013.

4.3. Body composition indication: Ibutamoren, tesamorelin, capromorelin, anamorelin, macimorelin

4.3.1. Ibutamoren

In a randomized clinical trial, ibutamoren for 12 months was well-tolerated and increased GH secretion, fat-free mass, but not muscle strength in healthy elderly subjects [75]. However, further development was discontinued because ibutamoren was associated with the risk of heart failure in a randomized trial to examine the safety and efficacy in patients with hip fracture [46].

4.3.2. Tesamorelin

Several randomized clinical trials have shown the beneficial effects of tesamorelin on impaired body composition in patients with HIV-associated lipodystrophy [76-79]. A meta-analysis including four clinical studies also revealed that tesamorelin decreased visceral fat and increased lean body mass in this population [80]. As a result, the FDA approved tesamorelin (Egrifta™) as the first-line treatment for the reduction of excessive abdominal fat in HIV-infected patients with lipodystrophy.

4.3.3. Capromorelin

A phase II clinical trial investigated the effects of capromorelin on body composition and functional performance in healthy elderly subjects. At 12 months, capromorelin significantly increased lean body mass and stair climbing power compared to placebo. However, this study was terminated early, because the results at 12 months were deemed not indicate continuation of this study [81]. As ageing the process is not considered a pathological condition by the FDA, capromorelin should offer outstanding results such as a survival benefit in this population or be applied for other clinical indications [82]. Capromorelin has so far been only approved by the FDA as a short-term therapeutic option for appetite improvement in anorexic dogs.

4.3.4. Anamorelin

Two double-blind, Phase III trials (ROMANA 1, NCT01387269, n=484; ROMANA 2, NCT01387282, n=495) assessed the efficacy and safety of anamorelin 100 mg in patients with incurable stage III/IV NSCLC and cachexia defined as ≥5% weight loss within the previous 6 months or a BMI <20 kg/m2 [56]. In both studies, anamorelin increased lean body mass compared to placebo (ROMANA 1: 1.10 kg for anamorelin, -0.44 kg for placebo; ROMANA 2: 0.75 kg for anamorelin, -0.96 kg for placebo; p<0.0001 for both), but did not significantly improve hand grip strength [56]. Subsequently, an extension study, ROMANA3 (NCT01395914), enrolling 513 patients with NSCLC from ROMANA1 and ROMANA2, evaluated the efficacy and safety of anamorelin for an additional 12 weeks. AS with prior studies, anamorelin was associated with a favorable safety profile as well as increased body weight but not muscle strength [83]. Anamorelin have shown similar results in a clinical trial enrolling patients with NSCLC-induced cachexia in Japan (Clinical trial registration: JapicCTI-111415 [Japan Pharmaceutical Information Center Clinical Trials Information]) [84]. Although several clinical studies have shown that anamorelin increased muscle mass, but not muscle strength, anamorelin has not been granted approval in 2017, despite the promising results in clinical studies, because increase in muscle mass without significant increase in muscle strength has not been considered acceptable.

5. Summary and outlook

Growth hormone secretagogues (GHSs) have been mainly selected for growth retardation, gastrointestinal dysfunction, and impaired body composition. However, in the field of growth retardation
and gastrointestinal dysfunction, GHSS have failed to show favorable results in several clinical trials with an exception of pramorelin, which was approved as a diagnostic tool of growth hormone deficiency in adults and children in Japan. On the other hand, GHSS could be hailed as a promising treatment option for altered body composition. Tesamorelin has been approved by the FDA for the treatment of lipodystrophy in HIV-infected patients. Since exercise training and nutritional support have shown favorable effects on muscle wasting in impaired body composition such as sarcopenia and cachexia, combination therapy of GHSS such as anamorelin with them appear promising. A high medical unmet need in these pathological conditions should be further investigated in clinical trials.

6. Acknowledgments

We acknowledge support by the German Research Foundation and the Open Access Publication Funds of the University of Göttingen. The authors certify that they comply with the ethical guidelines for authorship and publishing of the Journal of Cachexia, Sarcropenia and Muscle – Rapid Communications (von Haehling S, Ebner N, Morley JE, Coats AJ, Anker SD). Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcropenia and Muscle – Rapid Communications. J Cachexia Sarcropenia Muscle Rapid Communications 2017; 1:e44-1-2).

We acknowledge support by the German Research Foundation and the Open Access Publication Funds of the Göttingen University. We acknowledge support by the Open Access Publication Funds of the Göttingen University.

7. Conflict of interest

J. Ishida, M. Saitoh, and N. Ebner declare that they have no conflict of interest. S. von Haehling has been a paid consultant to Chugai Pharma and Helsinn Therapeutics.

References


growth hormone secretagogues: mechanism, history of action and clinical development